1. Home
  2. SABS vs PRE Comparison

SABS vs PRE Comparison

Compare SABS & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.71

Market Cap

288.8M

Sector

Health Care

ML Signal

HOLD

Logo Prenetics Global Limited

PRE

Prenetics Global Limited

HOLD

Current Price

$18.48

Market Cap

337.6M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
SABS
PRE
Founded
2014
2014
Country
United States
Hong Kong
Employees
86
98
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
288.8M
337.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SABS
PRE
Price
$3.71
$18.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$10.75
$30.50
AVG Volume (30 Days)
830.5K
228.6K
Earning Date
05-12-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$108.69
Revenue Next Year
N/A
$58.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.67
$7.18
52 Week High
$6.60
$23.63

Technical Indicators

Market Signals
Indicator
SABS
PRE
Relative Strength Index (RSI) 55.12 47.63
Support Level $3.48 $17.44
Resistance Level $4.10 $21.81
Average True Range (ATR) 0.24 1.50
MACD 0.04 -0.23
Stochastic Oscillator 61.80 31.76

Price Performance

Historical Comparison
SABS
PRE

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

About PRE Prenetics Global Limited

Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.

Share on Social Networks: